Secukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune diseases, including psoriasis, ankylosing spondylitis, and psoriatic arthritis. By inhibiting IL-17A, secukinumab reduces inflammation and helps to manage symptoms of these conditions.
